Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 204

Sort by

Sort Order Select

Journal Articles

Survival of Hemodialysis-Dependent Multiple Myeloma Patients and Factors Associated with Dialysis Independence: A Real-World Study in China

Chenyun Wang, Jinuo Wang, Yang Yang, Donghua He, Gaofeng Zheng, Xiaoyan Han, Jingsong He, Jinping Ying, Wenjun Wu, Zhen Cai

Blood (2024) 144 (Supplement 1): 6913.

https://doi.org/10.1182/blood-2024-201472

Published: 2024

Journal Articles

Study on the Molecular Genetic Characteristics of Multiple Myeloma Patients in China

Yang Yang, Jingsong He, Gaofeng Zheng, Xiaoyan Han, Yang Nie, Li Sun, Haoran Ma, Ying Wu, Jie Zhang, Zhen Cai

Blood (2024) 144 (Supplement 1): 6816.

https://doi.org/10.1182/blood-2024-202862

Published: 2024

Journal Articles

Altered Quantity and Function of Follicular T Helper Cell Subsets in Multiple Myeloma and MGUS

Jinuo Wang, Duoduo Zhao, Xingyuan Zhai, Wenjun Wu, Zhen Cai

Blood (2024) 144 (Supplement 1): 6812.

https://doi.org/10.1182/blood-2024-199044

Published: 2024

Journal Articles

E3 Ubiquitin Ligase TRIM21 Enhances Macrophage-Mediated Bortezomib Resistance By Inducing M2 Polarization in Multiple Myeloma

Wen Cao, Jing Chen, Enfan Zhang, Zhen Cai

Blood (2024) 144 (Supplement 1): 6829.

https://doi.org/10.1182/blood-2024-209627

Published: 2024

Journal Articles

Myeloma-Associated Macrophages Protect Tumor Cells By Reprogramming of Lipid Metabolism through SREBP1

Xing Guo, Zhenfeng Dai, Enfan Zhang, Zhen Cai

Blood (2024) 144 (Supplement 1): 6858.

https://doi.org/10.1182/blood-2024-210568

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Qingxiao Chen, Jiasheng Wang, Yang Yang, Gaofeng Zheng, Jing Chen, Xiaoyan Han, Li Yang, Wenjun Wu, YI LI, Donghua He, Jingsong He, Zhen Cai

Blood (2024) 144 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2024-197887

Published: 2024

Journal Articles

Single-Cell and Spatial Transcriptomics Link Malignant T Cells to Macrophages in the Tumor Immune Microenvironment of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Jinuo Wang, Zhongmin Zhang, Fei Cheng, Wenjun Wu, Zhaoming Wang, Luyi Tian, Zhen Cai

Blood (2024) 144 (Supplement 1): 6210.

https://doi.org/10.1182/blood-2024-193158

Published: 2024

Journal Articles

The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients

Yibo Wu, Xiaolin Yuan, Xiaoyu Lai, Lizhen Liu, Jimin Shi, Weiyan Zheng, Jian Yu, Yanmin Zhao, Jie Sun, Xiujin Ye, Zhen Cai, He Huang, Shanshan Pei, Yi Luo

Blood (2024) 144 (Supplement 1): 843.

https://doi.org/10.1182/blood-2024-209592

Published: 2024

Journal Articles

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 498.

https://doi.org/10.1182/blood-2024-193738

Published: 2024

Journal Articles

Anomalous Peaks Observed in the Mass Spectrometry of Light Chains Correlate with the Diagnosis of AL Amyloidosis

Mengmeng Dong, Xiao Xiao, Zhen Cai, Jiasheng Wang, Yang Yang, Gaofeng Zheng, Li Yang, Haimeng Yan

Blood (2024) 144 (Supplement 1): 6894.

https://doi.org/10.1182/blood-2024-210534

Published: 2024

Journal Articles

Bruton's Tyrosine Kinase (BTK) Inhibitors Plus RM (rituximab and methotrexate) for the First-Line Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Fangshu Guan, Xing Guo, Yi Li, Jing Chen, Jingsong He, Wenjun Wu, Zhen Cai, Yi Zhao

Blood (2024) 144 (Supplement 1): 6534.

https://doi.org/10.1182/blood-2024-212369

Published: 2024

Journal Articles

Clinical and Genetic Landscape of Peripheral T-Cell Lymphomas in Chinese Population: A Retrospective Study

Lingling Wang, Lei Yang, Fangshu Guan, Jing Chen, Yuexin Cheng, Yuqing Miao, Jingsong He, Zhen Cai, He Huang, Yi Zhao

Blood (2024) 144 (Supplement 1): 6181.

https://doi.org/10.1182/blood-2024-199127

Published: 2024

Journal Articles

A Positive Feedback Loop between YTHDC1 and EP300 Drives Tumorigenesis in Multiple Myeloma

Yifan Hou, Jianwei Qu, Enfan Zhang, Zhen Cai

Blood (2024) 144 (Supplement 1): 4647.

https://doi.org/10.1182/blood-2024-207016

Published: 2024

Journal Articles

Management of Acquired Hemophilia a in the Backdrop of Coronavirus Disease 19 and Multiple Myeloma

Zhen Cai, Mengmeng Dong, Jinna Zhang, Jiasheng Wang

Blood (2024) 144 (Supplement 1): 5508.

https://doi.org/10.1182/blood-2024-209916

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Yan Xu, Zhen Cai, Zhongjun Xia, Chen Yang, Jia Chen, Zewen Zhu, Xiaojuan Jing, Ji Tian, Nating Zhang, Ailing Cui, Jianxing Tang, Haolin Sun, Lugui Qiu

Blood (2024) 144 (Supplement 1): 3381.2.

https://doi.org/10.1182/blood-2024-200737

Published: 2024

Journal Articles

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Blood (2024) 144 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2024-200354

Published: 2024

Journal Articles

The c-MAF/SLP76 Axis Modulates Immune Evasion and Drives Malignancy in Multiple Myeloma Via Epigenetic Reprogramming

Zhenfeng Dai, Yunlu Jia, Jianbiao Zhou, Wee-Joo Chng, Zhen Cai

Blood (2024) 144 (Supplement 1): 3277.

https://doi.org/10.1182/blood-2024-206958

Published: 2024

NARROW

Survival of Hemodialysis-Dependent Multiple Myeloma Patients and Factors Associated with Dialysis Independence: A Real-World Study in China

Study on the Molecular Genetic Characteristics of Multiple Myeloma Patients in China

Altered Quantity and Function of Follicular T Helper Cell Subsets in Multiple Myeloma and MGUS

E3 Ubiquitin Ligase TRIM21 Enhances Macrophage-Mediated Bortezomib Resistance By Inducing M2 Polarization in Multiple Myeloma

Myeloma-Associated Macrophages Protect Tumor Cells By Reprogramming of Lipid Metabolism through SREBP1

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Single-Cell and Spatial Transcriptomics Link Malignant T Cells to Macrophages in the Tumor Immune Microenvironment of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Anomalous Peaks Observed in the Mass Spectrometry of Light Chains Correlate with the Diagnosis of AL Amyloidosis

Bruton's Tyrosine Kinase (BTK) Inhibitors Plus RM (rituximab and methotrexate) for the First-Line Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Clinical and Genetic Landscape of Peripheral T-Cell Lymphomas in Chinese Population: A Retrospective Study

A Positive Feedback Loop between YTHDC1 and EP300 Drives Tumorigenesis in Multiple Myeloma

Management of Acquired Hemophilia a in the Backdrop of Coronavirus Disease 19 and Multiple Myeloma

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

The c-MAF/SLP76 Axis Modulates Immune Evasion and Drives Malignancy in Multiple Myeloma Via Epigenetic Reprogramming

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only